AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer
Clinical Colorectal Cancer · 2026
DOI: 10.1016/j.clcc.2026.03.001 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Colorectal Cancer, 2026. Verfasst von Gertjan Rasschaert und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Oncology Department, Leuven University Hospitals, Leuven, Belgium; Laboratory for Digestive Oncology, Oncology Department, KU Leuven…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Adenocarcinoma. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
BACKGROUND: Recent evidence has suggested that neoadjuvant chemotherapy may provide clinical benefit for patients with locally advanced colon cancer. Immunotherapy may provide additive or synergistic effects when combined with chemotherapy. This study's objective is to assess the efficacy, safety, and tolerability of neoadjuvant dostarlimab in combination with capecitabine-oxaliplatin (CAPEOX) versus CAPEOX in patients with T4N0 or stage III mismatch repair proficient/microsatellite stable (pMMR/MSS) resectable colon cancer. METHODS: AZUR-4 (NCT06567782) is a multicenter, phase 2, open-label, randomized (3:1 ratio) study of 120 patients across multiple countries. Eligible patients are aged ≥ 18 years with resectable pMMR/MSS colon adenocarcinoma with no prior treatment. Four cycles (21 days) of CAPEOX ± dostarlimab will be administered as neoadjuvant treatment. After completing neoadjuvant treatment, patients will undergo surgery 3 to 6 weeks later, with additional adjuvant chemotherapy administered after surgery at the investigator's discretion; no additional dostarlimab will be administered. Primary endpoints are major pathological response, determined by local assessment, and safety. Secondary endpoints will assess the feasibility and pathological response to the regimen. Exploratory endpoints include biomarker readouts and pathological response rate in biomarker subsets. CONCLUSIONS: AZUR-4 will evaluate the effect of neoadjuvant dostarlimab + CAPEOX in patients with previously untreated T4N0 or stage III pMMR/MSS resectable colon cancer, a population for whom improved treatments are urgently needed. The robust sampling and advanced analysis of pretreatment and posttreatment blood, tissue, and tumor samples planned for this trial should assist in elucidating immune profile analyses to support the discovery of novel predictive biomarkers in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Oncology Department, Leuven University Hospitals, Leuven, Belgium; Laboratory for Digestive Oncology, Oncology Department, KU Leuven, Leuven, Belgium. Electronic address: gertjan.rasschaert@uzleuven.be.
- Laboratory for Digestive Oncology, Oncology Department, KU Leuven, Leuven, Belgium.
- Gastrointestinal Oncology Department, Leuven University Hospitals, Leuven, Belgium; Laboratory for Digestive Oncology, Oncology Department, KU Leuven, Leuven, Belgium.
- Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Pathology & Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
- ICON Central Laboratories, New York, NY.
- GSK, Collegeville, PA.
Förderung
- GlaxoSmithKline
Zitieren
APA
Rasschaert, G., Peddle, A. M., Verbandt, S., Tejpar, S., West, N. P., Ross, J., Switzky, J., Balas, M. M., Edwards, K., Kari, G., Griffin, S., Cohen, D. N., Hammatt, E., & Moon, E. K. (2026). AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.03.001
Vancouver
Rasschaert G, Peddle AM, Verbandt S, Tejpar S, West NP, Ross J, et al. AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.03.001
BibTeX
@article{Rasschaert2026,
author = {Rasschaert, Gertjan and Peddle, Allyson M and Verbandt, Sara and Tejpar, Sabine and West, Nicholas P and Ross, Jenny and Switzky, Julie and Balas, Morad Marco and Edwards, Ken and Kari, Gabor and Griffin, Sue and Cohen, Daniel N and Hammatt, Emily and Moon, Edmund K},
title = {AZUR-4, a Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Previously Untreated T4N0 or Stage III Mismatch Repair Proficient/Microsatellite Stable Resectable Colon Cancer},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.03.001}
}
EUVIMED